Botanix Pharmaceuticals Ltd BOT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$0.22
- Day Range
- A$0.22–0.23
- 52-Week Range
- A$0.08–0.24
- Bid/Ask
- A$0.22 / A$0.23
- Market Cap
- A$338.65 Mil
- Volume/Avg
- 1.5 Mil / 2.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 776.17
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Botanix Pharmaceuticals Ltd is a clinical-stage cannabinoid therapeutics company. The company's focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1308 - Plaque Psoriasis, BTX1204 - Atopic Dermatitis, and BTX 1701 - Mild Acne. The majority of Revenue is Derived from Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1
- Website
- https://www.botanixpharma.com
Comparables
Valuation
|
Metric
|
BOT
|
INVA
|
ITCI
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 9.24 | — |
Price/Book Value | 7.33 | 1.42 | 12.06 |
Price/Sales | 776.17 | 4.24 | 15.35 |
Price/Cash Flow | — | 7.95 | — |
Price/Earnings
BOT
INVA
ITCI
Financial Strength
|
Metric
|
BOT
|
INVA
|
ITCI
|
|---|---|---|---|
Quick Ratio | 8.09 | 7.28 | 4.95 |
Current Ratio | 9.50 | 9.03 | 5.41 |
Interest Coverage | −864.00 | 10.31 | — |
Quick Ratio
BOT
INVA
ITCI
Profitability
|
Metric
|
BOT
|
INVA
|
ITCI
|
|---|---|---|---|
Return on Assets (Normalized) | −24.90% | 14.79% | −13.47% |
Return on Equity (Normalized) | −27.30% | 29.29% | −15.88% |
Return on Invested Capital (Normalized) | −27.56% | 16.71% | −17.96% |
Return on Assets
BOT
INVA
ITCI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Yqjjjypr | Pqfm | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xhkdltgtw | Pgplvfn | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Clllqms | Yfymq | $99.6 Bil | |
MRNA
| Moderna Inc | Xqnkkklcy | Nbwp | $38.8 Bil | |
ARGX
| argenx SE ADR | Tdwkljdv | Vmrwk | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Lmzyxwwst | Pky | $21.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dgcpqvfzj | Ttdykt | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hnxwndxl | Nkjqvh | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xfvmrtqx | Sskvccg | $12.4 Bil | |
INCY
| Incyte Corp | Tbqhkmlk | Fqktr | $11.9 Bil |